Sanjay Popat, BSc, MBBS, FRCP, PhD, discusses the clinical implications of the final results of the phase 3 ALTA-1L trial in ALK-positive non–small cell lung cancer. Scroll to 0:07 in the video for Dr. Popat's topline points on the data.
Sanjay Popat, BSc, MBBS, FRCP, PhD, professor, consultant thoracic medical oncologist, The Royal Marsden, honorary clinical senior lecturer, Molecular Genetics and Genomics Group, National Heart and Lung Institute, Imperial College London, discusses the clinical implications of the final results of the phase 3 ALTA-1L trial (NCT02737501) in ALK-positive non–small cell lung cancer (NSCLC).
During the 2021 ESMO Congress, the final results of the ALTA-1L trial were presented virtually. The findings demonstrated consistent efficacy and safety with brigatinib (Alunbrig) vs crizotinib (Xalkori) in patients with ALK-positive NSCLC as reported in previous interim analyses. Brigatinib induced a 52% reduction in the risk of disease progression or death compared with crizotinib in this patient population, Popat says. Although overall survival data are maturing, a similar OS was observed in the brigatinib and crizotinib arms.
Additionally, high intracranial efficacy continued to be observed with brigatinib, which reduced the risk of intracranial progression by 56% in all patients and 71% in patients with baseline brain metastases vs crizotinib, Popat says.
Finally, treatment with brigatinib was associated with improved health-related quality of life compared with crizotinib, Popat concludes.
Sponsorship provided by Takeda/Content Developed Independently by OncLive